News FAMHP

There are 728 result(s) found based on your search criteria

41-50 from 728 result(s)

Coronavirus: weekly overview of 1 April 2021 on adverse reactions of COVID-19 vaccines

Every Thursday, the FAMHP publishes a cumulative overview of the adverse reactions reported after administration of a COVID-19 vaccine in Belgium. By being fully transparent, the FAMHP wants to increase confidence in COVID-19 vaccines.

Manufacturing and distribution authorisations and registrations of active pharmaceutical ingredients (API) distributed digitally

Manufacturing authorisations and/or distribution authorisations of medicines and registrations of active pharmaceutical ingredients are no longer automatically sent in paper format by post to the marketing authorisation holder. The FAMHP is now sending these documents in digital format by e-mail. Marketing authorisation holders can still request paper versions.

Coronavirus: weekly update of 30 March 2021 on vaccine deliveries and information on vaccination equipment

To increase transparency on the deliveries of COVID-19 vaccines and vaccination equipment, the FAMHP publishes the number of doses delivered to Belgium, how many of these doses are allocated to each of the federated entities and the size of the emergency stock. Also, regular updates are published on the number of needles and syringes that have been ordered and received.

Coronavirus: weekly overview of 25 March 2021 on adverse reactions of COVID-19 vaccines

Every Thursday, the FAMHP publishes a cumulative overview of the adverse reactions reported after administration of a COVID-19 vaccine in Belgium. By being fully transparent, the FAMHP wants to increase confidence in COVID-19 vaccines.

Flash VIG-news: recommendations for thrombocytopenia and coagulation disorders with COVID-19 Vaccine AstraZeneca

After further investigation of cases of thromboembolic events and other conditions related to blood clots reported after vaccination with COVID-19 Vaccine AstraZeneca, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has concluded that the benefits of the vaccine still outweigh the risks, despite possible link to rare blood clots with low blood platelets.

PRAC March 2021 - Benefits of ifosfamide solutions continue to outweigh risks

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has concluded that the benefits of ifosfamide solutions for infusion continue to outweigh their risks in the treatment of different types of cancers, including various solid tumours and blood cancers such as lymphomas (cancer of white blood cells).

Coronavirus: weekly update of 23 March 2021 on vaccine deliveries and information on vaccination equipment

To increase transparency on the deliveries of COVID-19 vaccines and vaccination equipment, the FAMHP publishes the number of doses delivered to Belgium, how many of these doses are allocated to each of the federated entities and the size of the emergency stock. Also, regular updates are published on the number of needles and syringes that have been ordered and received.

Coronavirus: EMA organises third public hearing on new COVID-19 vaccines

The European Medicines Agency (EMA) will organise a third public hearing on 26 March 2021 to inform European citizens about the assessment, approval, safety and impact of the COVID-19 vaccines in the EU.

Coronavirus: weekly overview of 18 March 2021 on adverse reactions of COVID-19 vaccines

Every Thursday, the FAMHP publishes a cumulative overview of the adverse reactions reported after administration of a COVID-19 vaccine in Belgium. By being fully transparent, the FAMHP wants to increase confidence in COVID-19 vaccines.

Coronavirus: benefits of COVID-19 Vaccine AstraZeneca still outweigh the risks despite possible link to rare blood clots with low blood platelets

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) completed the review of AstraZeneca’s COVID-19 vaccine. The review was carried out in the light of post-vaccination reports of thromboembolic events and other conditions related to blood clots.

41-50 from 728 result(s)